首页> 外文期刊>BJU international >Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy
【24h】

Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy

机译:患有变体组织学的上尿路尿路上皮癌患者的发病率和生存结果,并用肾上腺位切除术治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Objective To evaluate the incidence and survival outcomes of histological variants of upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU). Materials and Methods We retrospectively analysed data from 1610 patients treated with RNU for clinically non-metastatic UTUC between 1990 and 2016 in several centres participating in the UTUC Collaboration. Histological variants were classified as micropapillary, squamous, sarcomatoid and other, including other rare variants (<10 cases for each). Multivariable competing risk analyses were conducted to assess the effect of variant histology on overall recurrence and cancer-specific mortality (CSM). Results Overall, 1460 patients (91%) had pure urothelial carcinoma (PUC), whereas 150 (9%) were diagnosed with a variant histology, including 89 (5.0%), 41 (2.0%), 10 (1.0%) and 10 (1.0%) cases of micropapillary, squamous, sarcomatoid and other tumours, respectively. Variant histology was associated with the presence of adverse pathological features compared with PUC, including non-organ-confined disease (59% vs 38%; P < 0.001), lymph node invasion (28% vs 24%; P = 0.02), high-grade disease (88% vs 71%; P < 0.001), tumour necrosis (28% vs 16%; P = 0.001) and positive surgical margins (15% vs 8%; P = 0.01). In competing risk analysis, micropapillary variant was the only factor associated with worse recurrence (sub-hazard ratio [SHR] 2.27, 95% confidence interval [CI] 1.25-4.79; P = 0.02) whereas sarcomatoid variant was associated with worse CSM (SHR 16.8, 95% CI 6.86-41.17; P < 0.001). Conclusion We found that one out of 10 patients with UTUC treated with RNU had variant histology. Only micropapillary and sarcomatoid variants were associated with poorer oncological outcomes after adjusting for available confounding factors.
机译:目的评价用自由基肾脑切除术(RNU)处理的上部尿路上皮癌(UTUC)组织学变体的发病率和存活结果。我们回顾性分析了1990年至2016年间在参加UTUC合作的几个中心临床非转移UTUC治疗的1610例患者的数据和方法。组织学变体被归类为微小足球,鳞状,肉瘤样和其他,包括其他罕见的变体(每种含量<10例)。进行多变量竞争风险分析,以评估变体组织学对整体复发和癌症特异性死亡率(CSM)的影响。结果总体而言,1460名患者(91%)具有纯的尿路上皮癌(PUC),而150(9%)被诊断出具有变体组织学,其中89(5.0%),41(2.0%),10(1.0%)和10 (1.0%)微小足球,鳞状,卵石样品和其他肿瘤的病例。与PUC相比,变体组织学与不良病理特征的存在有关,包括非器官局限性疾病(59%vs 38%; p <0.001),淋巴结入侵(28%与24%; P = 0.02),高 - 疾病(88%vs 71%; p <0.001),肿瘤坏死(28%vs 16%; p = 0.001)和阳性手术边距(15%vs 8%; p = 0.01)。在竞争风险分析中,微杂种变体是与更差的复发相关的唯一因素(亚危害比[SHR] 2.27,95%置信区间[CI] 1.25-4.79; P = 0.02),而SARCAMATOID变异与更差的CSM(SHR 16.8,95%CI 6.86-41.17; P <0.001)。结论我们发现10名患有RNU治疗的术患者中的一项有变体组织学。在调整可用的混杂因素后,只有微血管和SARCAMATALID变异性与较差的肿瘤性结果有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号